American researchers are utilizing Israel’s massive cultivation facilities to conduct clinical trials testing the impact of cannabinoids (CBDs) on human disease. [tweet this] Ever since Dr. Mecholoulam’s discovery that CBDs are naturally produced by our endocannabinoid system, scientists from around the world have been working to show positive health impacts of synthetic and botanical CBDs in the human body.
So, the FDA does not currently approve plant-based medical cannabis research because the effects of plant-based medicine varies drastically from person to person. For a “drug-product” to receive FDA approval the effects must be consistent across consumers. Lucky for us, Breath of Life Pharma (BOL) based in Israel, offers researchers the opportunity to create consistent synthesized CBDs. They will soon be producing enough medical cannabis to supply the entire United States. With access to that much production power, they’ll be the fairy god-doctor of cannabis, doling out everything from capsules to inhalers.
From Cookies To Capsules
Not wanting to miss out on fairy god-doctor immortality, American scientists, like Alan Shackelford, have moved their research to Israel. Shackelford told the Westword in 2015 that, “Israel is the one place in the world that combines the scientific expertise, world-class universities and scientists.” Meanwhile, critics are concerned that distilling the plant for large-scale pharmaceutical distribution could not only decrease efficacy, but also decrease access due to potentially inflated costs. Only time will tell. In the meantime, the Israeli and American R&D relationship will only strengthen the potential health application of CBDs.